Skip to main content
Erschienen in: Supportive Care in Cancer 8/2016

03.06.2016 | Review Article

The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review

verfasst von: Thomas M. Atkinson, Sean J. Ryan, Antonia V. Bennett, Angela M. Stover, Rebecca M. Saracino, Lauren J. Rogak, Sarah T. Jewell, Konstantina Matsoukas, Yuelin Li, Ethan Basch

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials in cancer via the U.S. National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) for the purposes of ensuring patient safety. Recently, there has been a charge toward capturing the patient perspective for those AEs amenable to patient self-reporting via patient-reported outcomes (PRO). The aim of this review was to summarize the empirically reported association between analogous CTCAE and PRO ratings.

Methods

A systematic literature search was conducted using PubMed, EMBASE, Web of Science, and Cochrane databases through July 2015. From a total of 5658 articles retrieved, 28 studies met the inclusion criteria.

Results

Across studies, patients were of mixed cancer types, including anal, breast, cervical, chronic myeloid leukemia, endometrial, hematological, lung, ovarian, pelvic, pharyngeal, prostate, and rectal. Given this mixture, the AEs captured were variable, with many common across studies (e.g., dyspnea, fatigue, nausea, neuropathy, pain, vomiting), as well as several that were disease-specific (e.g., erectile dysfunction, hemoptysis). Overall, the quantified association between CTCAE and PRO ratings fell in the fair to moderate range and had a large variation across the majority of studies (n = 21).

Conclusions

The range of measures used and symptoms captured varied greatly across the reviewed studies. Regardless of concordance metric employed, reported agreement between CTCAE and PRO ratings was moderate at best. To assist with reconciliation and interpretation of these differences toward ultimately improving patient care, an important next step is to explore approaches to integrate PROs with clinician reporting of AEs.
Fußnoten
1
Questions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 16, 17, 18, 19, 20, and 26 from the Downs and Black Study Quality Checklist were used to assess quality.
 
Literatur
2.
Zurück zum Zitat Basch E (2014) New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 65:307–317CrossRefPubMed Basch E (2014) New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 65:307–317CrossRefPubMed
3.
4.
Zurück zum Zitat Basch E, Reeve BB, Mitchell SA, et al. (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106:dju244CrossRefPubMedPubMedCentral Basch E, Reeve BB, Mitchell SA, et al. (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106:dju244CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Basch E (2012) Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health 15:401–403CrossRefPubMed Basch E (2012) Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health 15:401–403CrossRefPubMed
6.
Zurück zum Zitat Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121–5127CrossRefPubMed Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121–5127CrossRefPubMed
8.
Zurück zum Zitat Hay JL, Atkinson TM, Reeve BB, et al. (2014) Cognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23:257–269CrossRefPubMed Hay JL, Atkinson TM, Reeve BB, et al. (2014) Cognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23:257–269CrossRefPubMed
9.
Zurück zum Zitat Dueck AC, Mendoza TR, Mitchell SA, et al. (2015) Validity and reliability of the U.S. National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1:1051–1059CrossRefPubMed Dueck AC, Mendoza TR, Mitchell SA, et al. (2015) Validity and reliability of the U.S. National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1:1051–1059CrossRefPubMed
10.
Zurück zum Zitat Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384CrossRefPubMedPubMedCentral Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Mandala M, Cremonesi M, Rocca A, et al. (2005) Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer 13:375–380CrossRefPubMed Mandala M, Cremonesi M, Rocca A, et al. (2005) Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer 13:375–380CrossRefPubMed
12.
Zurück zum Zitat Alberti P, Rossi E, Cornblath DR, et al. (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257–264CrossRefPubMed Alberti P, Rossi E, Cornblath DR, et al. (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257–264CrossRefPubMed
13.
Zurück zum Zitat Brabo EP, Paschoal ME, Biasoli I, et al. (2006) Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report. Qual Life Res 15:1519–1524CrossRefPubMed Brabo EP, Paschoal ME, Biasoli I, et al. (2006) Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report. Qual Life Res 15:1519–1524CrossRefPubMed
14.
Zurück zum Zitat Christodoulou M, McCloskey P, Stones N, et al. (2014) Investigation of a patient reported outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 112:244–249CrossRef Christodoulou M, McCloskey P, Stones N, et al. (2014) Investigation of a patient reported outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 112:244–249CrossRef
15.
Zurück zum Zitat Di Maio M, Gallo C, Leighl NB, et al. (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915CrossRefPubMed Di Maio M, Gallo C, Leighl NB, et al. (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915CrossRefPubMed
16.
Zurück zum Zitat Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol 22:3485–3490CrossRefPubMed Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol 22:3485–3490CrossRefPubMed
17.
Zurück zum Zitat Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. (2011) Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer 19:1421–1427CrossRefPubMed Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. (2011) Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer 19:1421–1427CrossRefPubMed
18.
Zurück zum Zitat Jensen K, Lambertsen K, Torkov P, et al. (2007) Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharyngeal cancer. Acta Oncol 46:1159–1168CrossRefPubMed Jensen K, Lambertsen K, Torkov P, et al. (2007) Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharyngeal cancer. Acta Oncol 46:1159–1168CrossRefPubMed
19.
Zurück zum Zitat Kirchheiner K, Nout R, Lindegaard J, et al. (2012) Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients. Strahlenther Onkol: Organ der Deutschen Rontgengesellschaft [et al] 188:933–939CrossRef Kirchheiner K, Nout R, Lindegaard J, et al. (2012) Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients. Strahlenther Onkol: Organ der Deutschen Rontgengesellschaft [et al] 188:933–939CrossRef
20.
Zurück zum Zitat Quinten C, Maringwa J, Gotay CC, et al. (2011) Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 103:1851–1858CrossRefPubMedPubMedCentral Quinten C, Maringwa J, Gotay CC, et al. (2011) Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 103:1851–1858CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Cella D, Huang H, Homesley HD, et al. (2010a) Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol 119:538–542CrossRefPubMed Cella D, Huang H, Homesley HD, et al. (2010a) Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol 119:538–542CrossRefPubMed
22.
Zurück zum Zitat Hirsh V, Okamoto I, Hon JK, et al. (2014) Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Thoracic Oncol Off Publ int Assoc Study Lung Cancer 9:83–90 Hirsh V, Okamoto I, Hon JK, et al. (2014) Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Thoracic Oncol Off Publ int Assoc Study Lung Cancer 9:83–90
23.
Zurück zum Zitat Shimozuma K, Ohashi Y, Takeuchi A, et al. (2009) Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17:1483–1491CrossRefPubMed Shimozuma K, Ohashi Y, Takeuchi A, et al. (2009) Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17:1483–1491CrossRefPubMed
24.
Zurück zum Zitat Atherton PJ, Burger KN, Loprinzi CL, et al. (2012) Using the Skindex-16 and common terminology criteria for adverse events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care Cancer 20:1729–1735CrossRefPubMed Atherton PJ, Burger KN, Loprinzi CL, et al. (2012) Using the Skindex-16 and common terminology criteria for adverse events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care Cancer 20:1729–1735CrossRefPubMed
25.
Zurück zum Zitat Neben-Wittich MA, Atherton PJ, Schwartz DJ, et al. (2011) Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys 81:397–402CrossRefPubMed Neben-Wittich MA, Atherton PJ, Schwartz DJ, et al. (2011) Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys 81:397–402CrossRefPubMed
26.
Zurück zum Zitat Basch E, Jia X, Heller G, et al. (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632CrossRefPubMedPubMedCentral Basch E, Jia X, Heller G, et al. (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Efficace F, Rosti G, Aaronson N, et al. (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99:788–793CrossRefPubMedPubMedCentral Efficace F, Rosti G, Aaronson N, et al. (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99:788–793CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Flores LT, Bennett AV, Law EB, et al. (2012) Patient-reported outcomes vs. clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res GCR 5:119–124PubMed Flores LT, Bennett AV, Law EB, et al. (2012) Patient-reported outcomes vs. clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res GCR 5:119–124PubMed
29.
Zurück zum Zitat Tom A, Bennett A, Rothenstein D, et al. (2013) Prevalence of patient-reported gastrointestinal symptoms and concordance with clinician toxicity assessments in radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 87:S570–S571CrossRef Tom A, Bennett A, Rothenstein D, et al. (2013) Prevalence of patient-reported gastrointestinal symptoms and concordance with clinician toxicity assessments in radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 87:S570–S571CrossRef
30.
Zurück zum Zitat Basch E, Iasonos A, McDonough T, et al. (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909CrossRefPubMed Basch E, Iasonos A, McDonough T, et al. (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909CrossRefPubMed
31.
Zurück zum Zitat Cirillo M, Venturini M, Ciccarelli L, et al. (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20:1929–1935CrossRefPubMed Cirillo M, Venturini M, Ciccarelli L, et al. (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20:1929–1935CrossRefPubMed
32.
Zurück zum Zitat Gravis G, Marino P, Joly F, et al. (2014) Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 50:953–962CrossRefPubMed Gravis G, Marino P, Joly F, et al. (2014) Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 50:953–962CrossRefPubMed
33.
Zurück zum Zitat Cella D, Pulliam J, Fuchs H, et al. (2003) Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98:406–412CrossRefPubMed Cella D, Pulliam J, Fuchs H, et al. (2003) Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98:406–412CrossRefPubMed
34.
Zurück zum Zitat Steinsvik EA, Fossa SD, Axcrona K, et al. (2010) Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer. J Urol 184:525–531CrossRefPubMed Steinsvik EA, Fossa SD, Axcrona K, et al. (2010) Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer. J Urol 184:525–531CrossRefPubMed
35.
Zurück zum Zitat Franklin HR, Simonetti GP, Dubbelman AC, et al. (1994) Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 5:113–117PubMed Franklin HR, Simonetti GP, Dubbelman AC, et al. (1994) Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 5:113–117PubMed
36.
Zurück zum Zitat Cella D, Riley W, Stone A, et al. (2010b) The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 63:1179–1194CrossRefPubMedPubMedCentral Cella D, Riley W, Stone A, et al. (2010b) The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 63:1179–1194CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Bennett BK, Park SB, Lin CS, et al. (2012) Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20:2959–2967CrossRefPubMed Bennett BK, Park SB, Lin CS, et al. (2012) Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20:2959–2967CrossRefPubMed
38.
Zurück zum Zitat Tang B, Giuliani M, Le LW, et al. (2013) Capturing acute toxicity data during lung radiotherapy by using a patient-reported assessment tool. Clin Lung Cancer 14:108–112CrossRefPubMed Tang B, Giuliani M, Le LW, et al. (2013) Capturing acute toxicity data during lung radiotherapy by using a patient-reported assessment tool. Clin Lung Cancer 14:108–112CrossRefPubMed
39.
Zurück zum Zitat Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26:1355–1363CrossRefPubMed Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26:1355–1363CrossRefPubMed
40.
Zurück zum Zitat Atkinson TM, Li Y, Coffey CW, et al. (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21:1159–1164CrossRefPubMed Atkinson TM, Li Y, Coffey CW, et al. (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21:1159–1164CrossRefPubMed
41.
Zurück zum Zitat Park JH, Kim YS, Park J, et al. (2014) Incidence and dose-volume analysis of acute bladder toxicity following pelvic radiotherapy. Tumori 100:195–200PubMed Park JH, Kim YS, Park J, et al. (2014) Incidence and dose-volume analysis of acute bladder toxicity following pelvic radiotherapy. Tumori 100:195–200PubMed
Metadaten
Titel
The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review
verfasst von
Thomas M. Atkinson
Sean J. Ryan
Antonia V. Bennett
Angela M. Stover
Rebecca M. Saracino
Lauren J. Rogak
Sarah T. Jewell
Konstantina Matsoukas
Yuelin Li
Ethan Basch
Publikationsdatum
03.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3297-9

Weitere Artikel der Ausgabe 8/2016

Supportive Care in Cancer 8/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.